Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 12 studies | 36% ± 19% | |
endothelial cell | 11 studies | 25% ± 10% | |
epithelial cell | 6 studies | 28% ± 19% | |
macrophage | 6 studies | 31% ± 8% | |
type I pneumocyte | 6 studies | 31% ± 11% | |
GABAergic neuron | 5 studies | 34% ± 17% | |
glutamatergic neuron | 4 studies | 42% ± 18% | |
neuron | 4 studies | 35% ± 14% | |
retinal ganglion cell | 4 studies | 42% ± 17% | |
smooth muscle cell | 4 studies | 21% ± 4% | |
fibroblast | 4 studies | 21% ± 7% | |
type II pneumocyte | 4 studies | 24% ± 5% | |
interneuron | 4 studies | 38% ± 18% | |
lymphocyte | 3 studies | 20% ± 2% | |
Mueller cell | 3 studies | 19% ± 4% | |
luminal cell of prostate epithelium | 3 studies | 20% ± 3% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 26% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 3293.02 | 966 / 966 | 99% | 30.88 | 524 / 527 |
esophagus | 99% | 2177.70 | 1436 / 1445 | 100% | 44.24 | 183 / 183 |
stomach | 100% | 1623.04 | 359 / 359 | 99% | 36.26 | 284 / 286 |
lung | 100% | 2783.32 | 578 / 578 | 99% | 32.26 | 1144 / 1155 |
thymus | 100% | 1926.40 | 653 / 653 | 98% | 19.52 | 593 / 605 |
uterus | 100% | 1583.10 | 170 / 170 | 98% | 24.12 | 449 / 459 |
brain | 98% | 1447.03 | 2594 / 2642 | 99% | 17.19 | 699 / 705 |
prostate | 100% | 1641.32 | 244 / 245 | 97% | 17.35 | 489 / 502 |
ovary | 99% | 1065.60 | 178 / 180 | 97% | 22.36 | 417 / 430 |
skin | 100% | 1820.21 | 1806 / 1809 | 95% | 18.06 | 447 / 472 |
pancreas | 97% | 780.13 | 318 / 328 | 97% | 18.94 | 173 / 178 |
breast | 100% | 1209.78 | 458 / 459 | 88% | 11.88 | 980 / 1118 |
bladder | 100% | 2273.90 | 21 / 21 | 87% | 19.00 | 437 / 504 |
kidney | 100% | 3236.65 | 89 / 89 | 83% | 15.80 | 752 / 901 |
liver | 99% | 1048.87 | 223 / 226 | 73% | 8.94 | 296 / 406 |
adrenal gland | 67% | 368.42 | 172 / 258 | 39% | 3.15 | 90 / 230 |
adipose | 100% | 1713.13 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 37.09 | 29 / 29 |
spleen | 100% | 2587.95 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 33.15 | 45 / 45 |
blood vessel | 100% | 2781.98 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 1106.35 | 816 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 81% | 10.00 | 65 / 80 |
peripheral blood | 73% | 1214.59 | 675 / 929 | 0% | 0 | 0 / 0 |
muscle | 61% | 375.69 | 492 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006954 | Biological process | inflammatory response |
GO_0034136 | Biological process | negative regulation of toll-like receptor 2 signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0007165 | Biological process | signal transduction |
GO_0034144 | Biological process | negative regulation of toll-like receptor 4 signaling pathway |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
GO_0034137 | Biological process | positive regulation of toll-like receptor 2 signaling pathway |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_1900181 | Biological process | negative regulation of protein localization to nucleus |
GO_0034121 | Biological process | regulation of toll-like receptor signaling pathway |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0035308 | Biological process | negative regulation of protein dephosphorylation |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005739 | Cellular component | mitochondrion |
GO_0005764 | Cellular component | lysosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0051721 | Molecular function | protein phosphatase 2A binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005525 | Molecular function | GTP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MFHAS1 |
Protein name | Malignant fibrous histiocytoma-amplified sequence 1 (Malignant fibrous histiocytoma-amplified sequence with leucine-rich tandem repeats 1) Alternative protein MFHAS1 |
Synonyms | MASL1 |
Description | FUNCTION: Probable GTP-binding protein . Functions in innate immunity and more specifically the inflammatory response as a regulator of the Toll-like receptor TLR2 and TLR4 signaling pathways . Negatively regulates the part of the TLR4 signaling pathway that leads to the activation of the transcription factor AP-1. By retaining the phosphatase complex PP2A into the cytoplasm, prevents the dephosphorylation of the AP-1 subunit JUN which is required for proper activation of the transcription factor . Both inhibits and activates the TLR2-dependent signaling pathway . Positively regulates the TLR2 signaling pathway to activate specifically the downstream p38 and JNK MAP kinases and promote the polarization of macrophages toward the pro-inflammatory M1 phenotype . It may also play a role in the regulation of inflammation induced by high glucose through the PKB/AKT signaling pathway . Also involved in erythrocyte differentiation through activation of the ERK1/ERK2 signaling pathway . . |
Accessions | Q9Y4C4 L8E7L4 ENST00000276282.7 |